Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review

다국어 초록 (Multilingual Abstract)

Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm. These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system. This cytokine storm can hence cause multi-organ dysfunction and life-threatening complications. Mavrilimumab is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. During an inflammation, Granulocyte-macrophage colony-stimulating factor (GM-CSF) release is crucial to driving both innate and adaptive immune responses. The GM-CSF immune response is triggered when an antigen attaches to the host cell and induces the signaling pathway. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia. With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.

참고문헌 (Reference)

1 Griffin JD, "The biology of GM-CSF:regulation of production and interaction with its receptor" 8 (8): 35-44, 1990

2 Broughton SE, "The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling" 250 : 277-302, 2012

3 Bonaventura A, "Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies" 1 : 1625-, 2020

4 U.S. National Library of Medicine, "Study of Mavrilimumab (KPL-301) in participants hopistalized with severe corona virus disease 2019 (COVID-19) pneumonia and hyper-inflammation"

5 Costela-Ruiz VJ, "SARS-CoV-2infection: The role of cytokines in COVID-19 disease" 54 : 62-75, 2020

6 Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor" 181 : 271-280, 2020

7 Singh Tomar PP, "SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine" 530 : 10-14, 2020

8 Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019pneumonia in Wuhan, China" 180 : 934-943, 2020

9 Trapnell BC, "Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages" 21 : 514-521, 2009

10 Zhou Y, "Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients" 2020

11 McClure BJ, "Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex" 101 : 1308-1315, 2003

12 Di Franco M, "Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis" 9 : 2014

13 Crotti C, "Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis" 28 : 573-581, 2019

14 . Burmester GR, "Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, doubleblind, placebo-controlled, phase I, first-in-human study" 70 : 1542-1549, 2011

15 Burmester GR, "Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis" 70 : 679-678, 2018

16 U.S. National Library of Medicine, "Mavrilimumab to reduce progression of acute respiratory failure in COVID-19 pneumonia and systemic hyper-inflmation. NCT04492514"

17 U.S. National Library of Medicine, "Mavrilimumab to reduce progression of acute respiratory failure in COVID-19 pneumonia and systemic hyper-inflammation. NCT04463004"

18 U.S National Library of Medicine, "Mavrilimumab in severe COVID-19 pneumonia and hyper-inflammation (COMBAT-19)"

19 Nicholls JM, "Lung pathology of fatal severe acute respiratory syndrome" 361 : 1773-1778, 2003

20 Cardone M, "Lessons learned to date on COVID-19 hyperinflammatory syndrome: considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation" 11 : 1131-, 2020

21 Cavalli G, "Interleukin-1 blockade with highdose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study" 2 : e325-e331, 2020

22 Lang FM, "GM-CSF-based treatments in COVID-19:reconciling opposing therapeutic approaches" 20 : 507-514, 2020

23 Hamilton JA, "GM-CSF in inflammation and autoimmunity" 23 : 403-408, 2002

24 De Luca G, "GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study" 2 : e465-e473, 2020

25 Hamilton JA, "GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential" 11 : 457-465, 2015

26 Takeuchi T, "Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study" 2 : 21-30, 2015

27 Cheng LL, "Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial" 181 : 71-78, 2021

28 Bhattacharya P, "Dual Role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy" 35 : 585-599, 2015

29 Ramani T, "Cytokines: the good, the bad, and the deadly" 34 : 355-365, 2015

30 Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" 395 : 497-506, 2020

31 Siddiqi HK, "COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal" 39 : 405-407, 2020

32 Lisi L, "Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2" 180 : 114169-, 2020

33 Weinblatt ME, "A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis" 70 : 49-59, 2018